Elaine Allison, CSP
Co-founder & CEO
Ms. Allison has over 25 years of experience in leadership roles, management consulting globally, and fund raising. She has been a serial entrepreneur since 1999 starting and managing several successful ventures. She implements effective business strategy utilizing a lean business model. Ms. Allison is also skilled at project management, risk management and raising capital. She is the author of a bestselling leadership book entitled, “The Velvet Hammer – PowHERful Leaderships Lessons for Women Who Don’t Golf”. Ms. Allison previously served in the role of Vice President of Business Development at Novelogics. She has been instrumental in creating the company, and setting the direction for all phases of growth.
Dr. Wayne Cheney, PhD
Co-founder, President and Chief Scientific Officer
Dr. Cheney has over 28 years of combined R&D experience with 18 years in the biopharmaceutical industry and another 10 years performing research in academic and government labs in both Canada and the U.S. Significantly, 12 years of his R&D experience have focused directly on oncology. Dr. Cheney was principal scientist and project leader for several successful discovery/pre-clinical development phase compounds for epilepsy, as well as for gout and cancer, while at Valeant Pharmaceuticals and Ardea Biosciences, respectively, and significantly helped translate these compounds into the clinic. Specifically, Potiga®/Trobalt® (Valeant/GSK) is now a marketed drug in the U.S. and EU for treatment of epileptic partial on-set seizures, while Ardea Biosciences’ (now Astra Zeneca) gout drug Zurampic® is marketed in the U.S. (now by Ironwood), and EU, and their oncology drug BAY 86-9766 reached phase II clinical testing with partner Bayer Healthcare AG.
Dr. Cheney received his PhD in Molecular Biology from the University of Wyoming (U.S.), a BSc in Biology from the University of Waterloo (Canada) and has performed post-doctoral research at Temple University (Fels Institute for Cancer Research) in Philadelphia, and at Canji, Inc. (a Schering-Plough subsidiary, now Merck) in San Diego. He has published a number of peer-reviewed scientific publications and has been named as co-inventor or inventor on four patents, and has others pending.
Dr. Neil Clendeninn, MD, PhD
Chief Medical Officer
Neil Clendeninn is an accomplished Senior Executive, Consultant, Board Member and Thought Leader with more than 35 years of success across the pharmaceutical, biotech, and medical industries. Leveraging extensive experience providing operations and regulatory guidance in drug development, he is a valuable asset for health-oriented companies working on preclinical development and early development learning technology pathways, going from preclinical to clinical concepts, shortening FDA approval processes, or on the clinical side of marketing. His broad areas of expertise include oncology, dermatology, HIV, drug development, and clinical research. Dr. Clendeninn received his BA (Biology and Chemistry) from Wesleyan University, Middletown, CT and his MD and PhD (Pharmacology) from New York University, NY. He trained at NCI (National Cancer Institute) in Oncology and specialized in new drug development.
Matthew Sebastiani, MBA (Finance)
VP Finance & Operations
Matthew attained his Masters of Business Administration in Finance from UBC’s Sauder School of Business, and was ranked among the top of his class, and also holds a B.A. (Hons) in Economics from SFU. He has years of experience in government, working as an Economic and Issues Advisor to the Deputy Leader in the Senate. He also worked in the private sector, working in financial services and insurance. He has previously worked with Novelogics Biotechnology in the area of finance and operations, and the Company is pleased to welcome him back.
Mark Bazett, PhD
Preclinical Immunotherapy Lead
Dr. Bazett is an experienced immunologist who specializes in preclinical drug development in oncology and inflammatory diseases. Previously, Dr. Bazett was the Director of Preclinical and Translational Research at Qu Biologics, a Vancouver based clinical stage biotech company, where he led the R&D team with a focus on oncology and inflammatory bowel disease. His research experience ranges from basic science, to IND enabling studies, and to translational research. Dr. Bazett obtained his PhD in Human Genetics from McGill University and a BSc in Microbiology and Biochemistry from the University of Victoria. His PhD focused on investigating the link between the bacteria that reside in the intestine, and the lung immune response in cystic fibrosis. Dr. Bazett research has led to numerous publications and patents in a range of different diseases and therapeutic areas including cancer, inflammatory bowel disease, asthma, COPD, pulmonary fibrosis and cystic fibrosis.
Dana Nohynek, MSc., RAC
Dana holds a Honors BSc from the University of Waterloo, a MSc from the University of Toronto and a RAC certification granted by the Regulatory Affairs Professionals Society (RAPS). She has over 15 years of industry experience that includes the development of regulatory strategies throughout various phases of clinical investigation, extensive interactions with regulatory authorities, preparation and submission of applications to health agencies in Canada, the United States and Europe. In addition, Dana has implemented a variety of quality systems, participated in agency audits, and developed internal training programs.
Dana works predominantly with start-up biotechnology, pharmaceutical and medical device companies as well as part-time for the CIHR-funded Canadian HIV Trials Network as Director for Regulatory Affairs & Quality Assurance.
Board of Directors
Mr. Cormack is an accomplished board member, executive and venture capitalist with almost three decades of experience in the biotechnology industry. Having served in executive positions for public and private life sciences companies, Mr. Cormack adds deep experience in the design and implementation of strategic growth plans, including mergers and acquisitions. Mr. Cormack has seventeen years of board service with multiple companies and organizations and seventeen years of CEO experience in four companies, including 8 years as a public company CEO. He was a co-founder of three biotechnology companies and has negotiated and completed multiple M&A transactions, dozens of strategic partner and licensing agreements and has raised hundreds of millions of equity capital through public and private transactions.
Mr. Cormack currently serves on the Board of Directors of Achieve Life Sciences, Inc. (NASDAQ: ACHV), The Vancouver Prostate Centre at Vancouver General Hospital, and The Prostate Centre’s Translation Research Initiative for Accelerated Discovery and Development. Mr. Cormack holds a B.S. degree from the University of Alberta.
Scientific Advisory Board
Dr. Randall Moreadith, MD, PhD
President and Chief Executive Officer, Serina Therapeutics, Inc. , AL, USA
SVP, Chief Development Officer, Nektar Therapeutics
Chief Medical Officer, Renovis , Inc.
Emma Guns (Scientific Advisor)
Department of Urologic Sciences
Faculty of Medicine
University of British Columbia
Co-Director, Pharmacology and Drug Design Senior Scientist Vancouver Prostate Centre
Wayne Cockburn (Advisor)
Managing Director, International Capital Management, Inc.
Some of our Partners & Contract Research Labs